Sporotrichosis: A forgotten disease in the drug research agenda

Expert Review of Anti-Infective Therapy

Volumn 2, Issue 1, 2004, Pages 85-94

  Bustamante, Beatriz ^a   Camposo, Pablo E ^a  

^a UNIVERSIDAD PERUANA CAYETANO HEREDIA   (Peru)

Author keywords

Itraconazole; Sporothrix schenckii; Sporotrichosis

Indexed keywords

ABELCET T; AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; ANIDULAFUNGIN; CASPOFUNGIN; ECHINOCANDIN B DERIVATIVE; FLUCONAZOLE; ITRACONAZOLE; KETOCONAZOLE; MELANIN; POSACONAZOLE; POTASSIUM IODIDE; RAVUCONAZOLE; TERBINAFINE; UNCLASSIFIED DRUG; VIRULENCE FACTOR; VORICONAZOLE;

ABDOMINAL PAIN; ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANGIONEUROTIC EDEMA; ANTIFUNGAL ACTIVITY; CENTRAL NERVOUS SYSTEM INFECTION; CLINICAL STUDY; CLINICAL TRIAL; COMMON COLD; DERMATOMYCOSIS; DEVELOPING COUNTRY; DIARRHEA; DISEASE COURSE; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG COST; DRUG EFFICACY; DRUG ERUPTION; DRUG MECHANISM; DRUG RESEARCH; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; DYSGEUSIA; DYSPEPSIA; EYE INFECTION; GASTROINTESTINAL SYMPTOM; GEOGRAPHIC DISTRIBUTION; HUMAN; HYPERTHERMIC THERAPY; INVESTMENT; LACRIMATION; LUNG INFECTION; MINIMUM INHIBITORY CONCENTRATION; NAUSEA; NEUTROPENIA; NONHUMAN; OBSTRUCTIVE JAUNDICE; OSTEOARTHROPATHY; PRESCRIPTION; REVIEW; SALIVARY GLAND DISEASE; SIDE EFFECT; SPOROTHRIX SCHENCKII; SPOROTRICHOSIS; STANDARD; THROMBOCYTOPENIA; THYROID DISEASE; TOXIC EPIDERMAL NECROLYSIS;

EID: 2942594306     PISSN: 14787210     EISSN: None     Source Type: Journal    
DOI: 10.1586/14787210.2.1.85     Document Type: Review

References (85)

1. Schenck BR. Refractory subcutaneous abscesses caused by a fungus possibly related to the sporoctrichia. Bull. Johns Hopkins Hosp. 9, 286-290 (1898).
2. Bustamante B, Campos PE. Endemic sporotrichosis. Curr. Opin. Infect. Dis. 14(2), 145-149 (2001).
3. Nusbaun BP, Gulbas N, Horwitz SN. Sporotrichosis acquired from a cat. J. Am. Acad. Dermatol. 8, 386-391 (1983).
4. Read SI, Sperling LC. Feline sporotrichosis: transmission to man. Arch. Dermatol. 118, 429-431 (1982).
5. Schwarz J, Kauffman CA. Occupational hazards from deep mycoses. Arch. Dermatol. 113, 1270-1275 (1977).
6. Cooper CR, Dixon DM, Salkin IF. Laboratory-acquired sporotrichosis. J. Med. Vet. Mycol. 30, 169-171 (1992).
7. Rippon JW. Sporotrichosis. In: Medical Mycology. The Pathogenic Fungi and the Pathogenic Actinomycetes (2nd Edition). WB Saunders Co., PA, USA 277-302 (1982).
8. Kwon-Chung KJ. Comparison of isolates of Sporothrix schenckii obtained from fixed cutaneous lesions with isolates from other types of lesions. J. Infect. Dis. 139, 424-431 (1979).
9. Sampaio SAP, Lacaz CS. Klinische und statistische untersuchungen über sporotrichose in Sao Paulo. Hautarzt 10, 490-493 (1959).
10. Pappas PG, Tellez I, Deep AE, Nolazco D, Holgado W, Bustamante B. Sporotrichosis in Perú: description of a Hyperendemic area. Clin. Infect. Dis. 30, 65-70 (2000).
11. Conti-Díaz IA. Sporotrichosis in Uruguay: Epidemiologic and Clinical Aspects. Proceedings of the Fifth International Conference on the Mycoses: superficial, cutaneous and subcutaneous infections. Caracas, Venezuela 27-30 April 1980. PAHO Scientific Publication No 396 312-321 (1980).
12. Mayorga R, Cáceres A, Toriello C et al. Investigación de una zona endémica de esporotricosis en la región de la Laguna de Ayarza, Guatemala. Bol. of Sanit. Panam. 87(1), 20-34 (1978).
13. Dismukes WE. Introduction to antifungal drugs. Clin. Infect. Dis. 30, 653-657 (2000).
14. Espinel-Ingroff A. In vitro activities of the new triazole Voriconazole (UK-109,496) against opportunistic filamentous and dimorphic fungi and common and emerging yeast pathogens. J. Clin. Microbiol. 36, 198-202 (1998).
15. Van Custem J, Van Gerven F, Janssen AJ. Activity of orally, topically and parenterally administered itraconazole in the treatment of superficial and deep mycoses: animal models. Rev. Infect. Dis. 9(Suppl. 1), S15-S32 (1987).
16. Restrepo A, Robledo J, Gomez I et al. Itraconazole therapy in lymphangitis and cutaneous sporotrichosis. Arch. Dermatol. 122, 413-417 (1986).
17. Meneses G, Bustamante B, Holgado W, de la Fuente J. Itraconazol en el tratamiento de la esporotricosis subcutanea. Boletin de la Sociedad Peruana de Medicina Interna, 5(1), 2-3 (1992).
18. Conti-Diaz I, Civita E, Gezuele E et al. Treatment of human cutaneous sporotrichosis with itraconazole. Mycoses 35, 153-156 (1992).
19. Sharkey-Mathis PK, Kauffman CA, Graybill JR et al. Treatment of Sporotrichosis with Itraconazole. Am. J. Med. 95, 279-285 (1993).
20. Noguchi H, Hiruma M, Kawada A. Case Report. Sporotrichosis successfully treated with itraconazole in Japan. Mycoses 42, 571-576 (1999).
21. Hull PR, Vismer HF. Treatment of cutaneous sporotrichosis with terbinafine. Br. J. Dermatol. 126(Suppl. 39), 51-55 (1992).
22. Chapman SW, Pappas P, Kauffmann C et al. Comparative evaluation of the efficacy and safety of two doses of terbinafine (500 and 1000 mg/day) in the treatment of cutaneous or lymphocutaneous sporotrichosis. Mycoses 47, (2004) (In Press).
23. Hall M, Monka C, Krupp P, O'Sullivan D. Safety of oral terbinafine: results of a post marketing surveillance study in 25,884 patients. Arch. Derm. 133, 1213-1219 (1997).
24. Diaz M, Negroni R, Montero-Gei F et al. A Pan-American 5-year study of fluconazole therapy for deep mycoses in the immunocompetent host. Clin. Infect. Dis. 14(Suppl. 1), S68-S76 (1992).
25. Castro LGM, Belda W, Cucé LC, Sampaio SAP, Stevens DA. Successful treatment of sporotrichosis with oral fluconazole: a report of three cases. Br. J. Dermatol. 128, 352-356 (1993).
26. Kauffman CA, Pappas PG, McKinsey DS et al. Treatment of lymphocutaneous and visceral sporotrichosis with fluconazole. Clin. Infect. Dis. 22(1), 46-50 (1996).
27. Cullen SI, Mauceri AA, Warner N. Successful treatment of disseminated cutaneous sporotrichosis with ketoconazole. J. Am. Acad. Dermatol. 27, 463-464 (1992).
28. Dismukes WE, Stamm AM, Graybill JR et al. Treatment of systemic mycoses with Ketoconazole: Emphasis on toxicity and clinical response in 52 patients. Ann. Intern. Med. 98, 13-20 (1983).
29. Urabe H, Nagashima T. Mechanism of antifungal action of potassium iodide on sporotrichosis. Dermatologia Internationalis 8, 36-39 (1969).
30. Itoh M, Okamoto S, Kariya H. Survey of 200 cases of sporotrichosis. Dermatologica 172, 209-213 (1986).
31. Meneses G, Cabezas C, Bustamante B et al. Reporte de 261 casos de esporotricosis entre 1987 y 1989. Centro Medico Santa Teresa, Abancay, Peru. Presented at the V Congreso Panamericano de Infectologia, Lima, Peru, April 7-10 (1991) (Abstract VI-9).
32. Cabezas C, Bustamante B, Holgado W, Begué R. Treatment of cutaneous sporotrichosis with one daily dose of potassium iodide. Pediatr. Infect. Dis. J. 15, 352-354 (1996).
33. Hiruma M, Kawada A, Noguchi H, Ishibashi A, Conti Diaz IA. Hyperthermic treatment of sporotrichosis: experimental use of infrared and far infrared rays. Mycoses 35(11-12), 293-299 (1992).
34. Sterling JB, Haymann WR. Potassium iodide in dermatology. A 19th century drug for the 21th century uses, pharmacology, adverse effects and contraindications. J. Am. Acad. Dermatol. 43, 691-697 (2000).
35. Pluss JL, Opal SM. Pulmonary sporotrichosis: review of treatment an outcome. Medicine 65(3), 143-153 (1986).
36. Ramirez J, Byrd RP, Roy TM. Chronic cavitary pulmonary sporotrichosis: efficacy of oral Itraconazole. J. Ky. Med. Assoc. 96, 103-105 (1998).
37. Ridgeway NA, Whitcomb FC, Erickson EE, Law SW. Primary pulmonary sporotrichosis. Report of two cases. Am. J. Med. 32, 153-160 (1962).
38. Lynch, PJ, Voorhes JJ, Harrell RE. Systemic sporotrichosis. Ann. Intern. Med. 73, 23-30 (1970).
39. Breeling JL, Weinstein L. Pulmonary sporotrichosis treated with itraconazole. Chest 103(1), 313-314 (1993).
40. Dall L, Salzman G. Treatment of pulmonary sporotrichosis with ketoconazole. Rev. Infect. Dis. 9, 795-798 (1987).
41. Carrada-Bravo T. Update on sporotrichosis. Aust. Fam. Physician 24(6), 1070-1071 (1996).
42. Bayer AS, Scott VJ, Guze LB. Fungal arthritis: sporotrichal arthritis. Semin. Arthritis Rheum. 9, 60-74 (1979).
43. Howell SJ, Toohey JST. Sporotrichal arthritis in South Central Kansas. Clin. Orthop. 346, 207-214 (1998).
44. Winn RE. A contemporary view of sporotrichosis. Curr. Top. Med. Mycol. 6, 73-94 (1995).
45. Downs NH, Hinthorn DR, Mhatre VR, Liu C. Intra-articular Amphotericin B treatment of Sporothrix schenckii arthritis. Arch. Intern. Med. 149, 954-955 (1989).
46. Badley AD, van Scoy RE. Long-term follow-up of multifocal osteoarticular sporotrichosis treated with itraconazole. Clin. Infect. Dis. 23(2), 394-395 (1996).
47. DeHart DJ. Use of itraconazole for treatment of sporotrichosis involving a knee prosthesis. Clin. Infect. Dis. 21(2), 450 (1995).
48. Horsburgh CR, Cannady PB, Kirkpatrick CH. Treatment of fungal infection in the bones and joints with Ketoconazole. J. Infect. Dis. 147 (6), 1064-1069 (1983).
49. Calhoun DL, Waskin H, White MP et al. Treatment of systemic sporotrichosis with ketoconazole. Rev. Infect. Dis. 13(1), 47-51 (1991).
50. Graybill JR, Craven PC, Donovan W, Matthew EB. Ketoconazole therapy of systemic fungal infections. Inadequacy of standard dosage regimens. Ann. Rev. Repir. Dis. 126, 171-174 (1982).
51. Lipstein-Kresch E, Isemberg HD, Singer C, Cooke O, Greenwald RA. Disseminated Sporothrix schenckii infection with arthritis in a patient with acquired immunodeficiency syndrome. J. Rheumatol. 12, 805-808 (1985).
52. Bibler MR, Luber HJ, Glueck HI, Estes SA. Disseminated sporotrichosis in a patient with HIV infection after treatment for acquired Factor VIII inhibitor. JAMA 256, 3125-3126 (1986).
53. Fitzpatrick JE, Eubanks S. Acquired immunodeficiency syndrome presenting as disseminated cutaneous sporotrichosis. Int. J. Dermatol. 27, 406-407 (1988).
54. Kurosawa A, Pollock SC, Collins MP, Kraff CR, Tso MO. Sporothrix schenckii endophthalmitis in a patient with human immunodeficiency virus infection. Arch. Ophtalmol. 106, 376-380 (1988).
55. Shaw JC, Levinson W, Montanaro A. Sporotrichosis in the acquired immunodeficiency syndrome. J. Am. Acad. Dermatol. 21, 1145-1147 (1989).
56. Heller HM, Fuhrer J. Disseminated sporotrichosis in patients with AIDS: case report and review of the literature. AIDS 5, 1243-1246 (1991).
57. Keiser P, Whittle D. Sporotrichosis in human immunodeficiency virus-infected patients: report of a case. Rev. Infect. Dis. 13, 1027-1028 (1991).
58. Oscherwitz SL, Rinaldi MG. Disseminated sporotrichosis in a patient infected with human immunodeficiency virus. Clin. Infect. Dis. 15, 568-569 (1992).
59. Penn CC, Goldstein E, Bartholomew WR. Sporothrix schenckii in a patient with AIDS. Clin. Infect. Dis. 15, 741-743 (1992).
60. Bolao F, Podzamczer D, Ventin M, Gudiol F. Efficacy of acute phase and maintenance therapy with itraconazole in an AIDS patient with sporotrichosis. Eur. J. Clin. Microbiol. Infect. Dis. 13, 609-612 (1994).
61. Donabedian H, O'Donnell E, Olszewski C, Mac Arthur R, Budd N. Disseminated cutaneous and meningeal sporotrichosis in an AIDS patient. Diagn. Microbiol. Infect. Dis. 18, 111-115 (1994).
62. Dong JA, Chren MM, Elewski BE. Bonsai tree: risk factor for disseminated sporotrichosis. J. Am. Acad. Dermatol. 33 (5 Pt.1), 839-840 (1995).
63. Rotz LD, Slater LN, Wack MF, Boyd AL, Scott EN, Greenfield RA. Disseminated sporotrichosis with meningitis in a patient with AIDS. Infect. Dis. Clin. Practice 5, 566-568 (1996).
64. Morgan M. Reves R. Invasive sinusitis due to Sporothrix schenckii, in a patient with AIDS. Clin. Infect. Dis. 23, 1319-1320 (1996).
65. Ticoras CJ, Schroeter AL, Hornbeck KL. Disseminated ulcerated papules and nodules. Cutaneous disseminated sporotrichosis. Arch. Dermatol. 132(8), 963-964 (1996).
66. Gori S, Lupetti A, Moscato G, Parenti M, Lofaro A. Pulmonary sporotrichosis with hyphae in a human immunodeficiency virus-infected patient. A case report. Acta Cytol. 41, 519-521 (1997).
67. Al-Tawfiq JA, Kara K. Wools. Disseminated sporotrichosis and Sporothrix schenckii fungemia as the initial presentation of human immunodeficiency virus infection. Clin. Infect. Dis. 26, 1403-1406 (1998).
68. Goldani LZ, Aquino VR, Dargel AA. Disseminated cutaneous sporotrichosis in an AIDS patient receiving maintenance therapy with fluconazole for previous cryptococcal meningitis. Clin. Infect. Dis. 28, 1337-1338 (1999).
69. Neto RJP, Machado AA, Castro G, Quaglio ASS, Martínez R. Esporotricose cutánea diseminada como manifestacao inicial da síndrome da imunodeficiencia adquirida: relato de caso. Rev. Soc. Bras. Med. Trop. 32, 57-61 (1999).
70. Ware AJ. Cockerell CJ, Skiest DJ, Kussman HM. Disseminated sporotrichosis with extensive cutaneous involvement in a patient with AIDS. J. Am. Acad. Dermatol. 40, 350-351 (1999).
71. Edwards C, Reuther WL 3rd, Greer DL. Disseminated osteoarticular sporotrichosis treatment in a patient with acquired immunodeficiency syndrome. South. Med. J. 93, 803-806 (2000).
72. Bonifaz A, Peniche A, Mercadillo P, Saúl A. Successful treatment of AIDS-related disseminated cutaneous sporotrichosis with itraconazole. AIDS Patient Care STDs 15, 603-606 (2001).
73. Aarestrup FM, Guerra RO, Vieira BJ, Cunha RM. Oral manifestation of sporotrichosis in AIDS patients: case report. Oral Dis. 7, 134-136 (2001).
74. Rocha MM, Dassin T, Lira R, Lima EL, Severo LC, Londero AT. Sporotrichosis in patient with AIDS: report of a case and review. Rev. Iberoam. Micol. 18, 133-136 (2001).
75. Carvalho MT, de Castro AP, Baby C, Werner B, Filus Neto J, Queiroz-Telles F. Disseminated cutaneous sporotrichosis in a patient with AIDS: report of a case. Rev. Soc. Bras. Med. Trop. 35, 655-659 (2002).
76. Kauffman CA. Sporotrichosis. Clin. Infect. Dis. 29, 231-237 (1999).
77. Hampton DE, Adesina A, Chodosh J. Conjunctival sporotrichosis in the absence of antecedent trauma. Cornea 21(8), 831-833 (2002).
78. Vieira-Dias D, Sena CM, Oréfice F, Tanure MAG, Hamdan JS. Ocular and concomitant cutaneous sporotrichosis. Mycoses 40, 197-201 (1997).
79. Gottlieb GS, Lesser CF, Holmes KK, Wald A. Disseminated sporotrichosis associated with treatment with immunosuppressants and tumor necrosis factor-α antogonists. CID 37, 838-840 (2003).
80. Espinel-Ingroff A. Comparison of in vitro activities of the new triazole SCH56592 and the echinocandins MK-0991 (L-743,872) and LY-303366 against opportunistic filamentous and dimorphic fungi and yeasts. J. Clin. Microbiol. 36, 2950-2956 (1998).
81. Ghannoum MA, Kuhn DM. Voriconazole - better chances for patients with invasive mycoses. Eur. J. Med. Res. 7, 242-256 (2002).
82. Mc Ginnis MR, Nordoff N, Li RK, Pasarell L, Warnock DW. Sporothrix schenckii sensitivity to voriconazole, itraconazole and amphotericin B. Med. Mycol, 39, 369-371 (2001).
83. Fung-Tomc JC, Huczko E, Minassian B, Bonner DP. In vitro activity of a new oral triazole, BMS-207147 (ER-30346). Antimicrob. Agents Chemother. 42, 313-318 (1998).
84. Morris Jones R, Youngchin S, Gomez BL et al. Synthesis of melanin-like pigments by Sporothrix schenckii in vitro and during mammalian infection. Infect. Immun. 71(7), 4026-4033 (2003).
85. Romero-Martinez R, Wheeler M, Guerrero-Plata A et al. Biosynthesis and functions of melanin in Sporothrix schenckii. Infect. Immun. 68, 3696-3703 (2000).